[译文]免疫介导疾病患者的生物疗法知识。BIOINFO 研究。

IF 1 Q4 PHARMACOLOGY & PHARMACY

FARMACIA HOSPITALARIA Pub Date : 2025-01-01 DOI:10.1016/j.farma.2024.08.002

Carlos Seguí-Solanes , Lidia Estrada , Esther Ramírez Herráiz , Silvia Ruiz-García , Tomás Palanques-Pastor , Vicente Merino Bohórquez , Cristina Capilla Montes , Joaquín Borras-Blasco

{"title":"[译文]免疫介导疾病患者的生物疗法知识。BIOINFO 研究。","authors":"Carlos Seguí-Solanes , Lidia Estrada , Esther Ramírez Herráiz , Silvia Ruiz-García , Tomás Palanques-Pastor , Vicente Merino Bohórquez , Cristina Capilla Montes , Joaquín Borras-Blasco","doi":"10.1016/j.farma.2024.08.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>To determine the degree of knowledge about biological therapy and biosimilars in patients with immune-mediated inflammatory diseases treated in Outpatient Pharmaceutical Care Units.</div></div><div><h3>Methods</h3><div>Observational, prospective, and multicenter study during the period May 2020–March 2021. A survey (9 questions) was conducted before starting treatment in which the patients' level of knowledge about biological therapy and biosimilars was assessed.</div></div><div><h3>Results</h3><div>A total of 169 patients were included in the study. The average value for the different questions was 3.3±0.6 out of 5, while the average final result was 29.4 points out of 45. 64.5% of the patients had an acceptable level before starting the medication (>27 points). The multivariate analysis showed a statistically significant correlation (<em>p</em>     <.05) with a better score at the beginning of treatment in those patients whose prescribing service was Rheumatology.</div></div><div><h3>Conclusions</h3><div>In general, the level of knowledge prior to biological therapy in patients is acceptable, being higher in dosage and administration technique related-factors and what is related to the dosage and administration technique and where to find information related to the medication; the worst rated were those on biosimilars-related. The factor of being followed by rheumatology, was associated with better knowledge.</div></div>\",\"PeriodicalId\":45860,\"journal\":{\"name\":\"FARMACIA HOSPITALARIA\",\"volume\":\"49 1\",\"pages\":\"Pages T32-T36\"},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"FARMACIA HOSPITALARIA\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1130634324001375\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"FARMACIA HOSPITALARIA","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1130634324001375","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

摘要

目的确定在门诊医药护理病房接受治疗的免疫介导炎症性疾病患者对生物疗法和生物仿制药的了解程度：2020年5月至2021年3月期间的观察性、前瞻性和多中心研究。在开始治疗前进行一项调查（9 个问题），评估患者对生物疗法和生物仿制药的了解程度：结果：共有 169 名患者参与了研究。不同问题的平均值为（3.3±0.6）分（满分 5 分），最终平均结果为 29.4 分（满分 45 分）。64.5%的患者在开始服药前的血糖水平为可接受水平（>27 分）。多变量分析显示，两者之间存在统计学意义上的显著相关性（p 结论：总体而言，患者在接受生物治疗前的知识水平是可以接受的，但在剂量和给药技术相关因素、剂量和给药技术相关内容以及在哪里可以找到与药物相关的信息方面的知识水平较高；评分最差的是与生物仿制药相关的知识。由风湿病学专家跟踪服务这一因素与更好的知识有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

[Translated article] Knowledge of biological therapy in patients with immune-mediated diseases. BIOINFO study

Objective

To determine the degree of knowledge about biological therapy and biosimilars in patients with immune-mediated inflammatory diseases treated in Outpatient Pharmaceutical Care Units.

Methods

Observational, prospective, and multicenter study during the period May 2020–March 2021. A survey (9 questions) was conducted before starting treatment in which the patients' level of knowledge about biological therapy and biosimilars was assessed.

Results

A total of 169 patients were included in the study. The average value for the different questions was 3.3 ± 0.6 out of 5, while the average final result was 29.4 points out of 45. 64.5% of the patients had an acceptable level before starting the medication (> 27 points). The multivariate analysis showed a statistically significant correlation (p < .05) with a better score at the beginning of treatment in those patients whose prescribing service was Rheumatology.

Conclusions

In general, the level of knowledge prior to biological therapy in patients is acceptable, being higher in dosage and administration technique related-factors and what is related to the dosage and administration technique and where to find information related to the medication; the worst rated were those on biosimilars-related. The factor of being followed by rheumatology, was associated with better knowledge.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

FARMACIA HOSPITALARIA PHARMACOLOGY & PHARMACY-

CiteScore

1.90

自引率

21.40%

发文量

审稿时长

37 days

期刊介绍： Una gran revista para acceder a los mejores artículos originales y revisiones de la farmacoterapia actual. Además, es Órgano de expresión científica de la Sociedad Española de Farmacia Hospitalaria, y está indexada en Index Medicus/Medline, EMBASE/Excerpta Médica, Alert, Internacional Pharmaceutical Abstracts y SCOPUS.